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INTRODUCTION
============

Hyperphosphatemia is a common metabolic complication in patients receiving dialysis that results from impaired kidney function and inability of conventional hemodialysis to sufficiently remove the daily dietary phosphate load \[[@gfy061-B1]\]. Fibroblast growth factor 23 (FGF23) regulates phosphate homeostasis (reviewed by Wolf \[[@gfy061-B2]\]). It is secreted by osteocytes and osteoblasts, and stimulates urinary phosphate excretion by downregulating phosphate reabsorption in the renal proximal tubule \[[@gfy061-B2]\]. FGF23 also suppresses circulating concentrations of 1,25-dihydroxyvitamin D by inhibiting its production in the kidney and accelerating its degradation \[[@gfy061-B3], [@gfy061-B4]\]. The resultant deficiency of 1,25-dihydroxyvitamin D contributes to secondary hyperparathyroidism \[[@gfy061-B5]\]. Factors known to stimulate FGF23 production include dietary phosphate and calcium intake, elevated serum calcium concentrations, administration of 1,25-dihydroxyvitamin D or its analogs, iron deficiency and inflammation \[[@gfy061-B6], [@gfy061-B7]\]. Serum FGF23 concentrations increase substantially as kidney function declines such that patients with end-stage renal disease receiving dialysis can have levels that are more than 1000-fold higher than those of healthy individuals \[[@gfy061-B8]\].

Like hyperphosphatemia \[[@gfy061-B9]\], elevated serum FGF23 concentration is strongly associated with cardiovascular disease and mortality in patients with chronic kidney disease (CKD) Stages 2--5D \[[@gfy061-B9]\]. In the Chronic Renal Insufficiency Cohort study of patients with CKD Stages 2--4, elevated FGF23 was independently associated with left ventricular hypertrophy (LVH) \[[@gfy061-B10]\], heart failure \[[@gfy061-B13]\], atrial fibrillation \[[@gfy061-B14]\] and mortality \[[@gfy061-B12]\]. Animal data support a possible causal role for FGF23 excess in the development of LVH, with FGF23 having been shown to cause pathological hypertrophy of rat cardiomyocytes *in vitro* and LVH *in vivo* \[[@gfy061-B10]\]. In contrast, it has also been suggested that cardiac hypertrophy occurs independently of FGF23 \[[@gfy061-B15]\]. FGF23 has also been shown to impair monocyte and neutrophil function \[[@gfy061-B16], [@gfy061-B17]\]. This may explain the increased risk of infection-related mortality associated with elevated FGF23 \[[@gfy061-B18]\], although it is possible that FGF23 may be upregulated in response to infection \[[@gfy061-B19]\]. It has also been shown that treatments that solely target FGF23 reduction, including neutralizing anti-FGF23 antibodies, precipitate severe hyperphosphatemia, and accelerate vascular calcification and mortality \[[@gfy061-B20]\]. Collectively, these data demonstrate the need to identify therapies capable of jointly lowering both serum phosphate and FGF23 concentrations.

Dietary phosphate restriction and administration of phosphate binders are first-line treatments for managing hyperphosphatemia in patients receiving hemodialysis. However, the ability to effectively reduce dietary phosphate intake is hampered by supplementation of the food supply with inorganic phosphate-based food additives and the expanding list of common items to which phosphate has been added (e.g. flavored water and other beverages) \[[@gfy061-B21]\]. These phosphate sources remain largely 'hidden' because they are not quantified on food labels and are unaccounted for by dietary data collection instruments and nutritional databases. Furthermore, the effects of phosphate binders on serum FGF23 concentrations have been inconsistent. While non-calcium-based binders variably lower serum FGF23 concentrations by up to 40%, calcium-based binders have minimal FGF23-lowering effects and may actually increase FGF23, perhaps owing to the FGF23-stimulatory effects of calcium loading (reviewed in Isakova *et al.* \[[@gfy061-B22]\]).

Tenapanor is a small-molecule inhibitor of the sodium/hydrogen exchanger isoform 3. In addition to lowering gastrointestinal absorption of sodium \[[@gfy061-B23]\], tenapanor also decreases gastrointestinal absorption of phosphate \[[@gfy061-B24], [@gfy061-B26]\] via a mechanism distinct from luminal phosphate binding, the details of which are under active investigation. We recently reported that tenapanor treatment significantly and dose-dependently decreased serum phosphate in a Phase 2 study of patients receiving hemodialysis with hyperphosphatemia \[[@gfy061-B27]\]. Here, we describe a secondary analysis of serum FGF23 concentrations during the Phase 2 clinical trial. We tested the hypothesis that tenapanor decreases serum FGF23 in parallel with serum phosphate.

MATERIALS AND METHODS
=====================

Study design and patients
-------------------------

The design and methods of this randomized, double-blind, placebo-controlled, multicentre Phase 2B study (EudraCT no. 2013--004319--33; ClinicalTrials.gov identifier NCT02081534) have been previously described \[[@gfy061-B27]\]. In brief, patients with CKD Stage 5D (receiving hemodialysis) on a stable dose of phosphate binders and with serum phosphate concentrations of 3.5--8.0 mg/dL were screened. After a 1- to 3-week washout of phosphate binders, patients with serum phosphate concentrations of 6.0 to \<10 mg/dL who had an increase of at least 1.5 mg/dL from screening after 1, 2 or 3 weeks of phosphate-binder washout were randomly assigned to 4 weeks of treatment with placebo or one of six tenapanor regimens (3 or 30 mg once daily, or 1, 3, 10 or 30 mg twice daily). The study was performed in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines. The protocol was approved by independent ethics committees. All participants provided written informed consent.

Study endpoints and assays
--------------------------

The primary efficacy endpoint of the trial was change in serum phosphate concentration from the end of the phosphate-binder washout period (baseline) to the end of treatment or early termination. FGF23 was a secondary exploratory biomarker. For the analysis of serum FGF23 concentrations, blood samples were collected before dialysis at screening, post-washout and at the end of treatment or early termination. Intact human FGF23 was measured by enzyme-linked immunosorbent assay (EMD Milipore, Billerica, MA, USA). All samples were stored at −80°C until analysis, which was conducted in one batch at the end of the study in duplicate \[inter-assay and intra-assay coefficients of variation (CVs) \<11%\] \[[@gfy061-B28]\]. Samples were diluted 1:20 for analysis, except for one individual's sample that required 1:100 dilution. Validation of linear dilution was performed using test samples containing high FGF23 concentrations to confirm that the signal was independent of the dilution (i.e. there was no plasma matrix effect).

Statistical analyses
--------------------

Owing to the highly right-skewed data, we calculated geometric means for all FGF23 measurements, and presented the geometric CV, along with medians, ranges and ratios of geometric means (with 95% confidence limits). All inferential analyses were performed using natural log-transformed FGF23 data.

We used an analysis of covariance (ANCOVA) to identify potential factors associated with serum FGF23 concentrations at screening. Candidate factors included age, sex, race/ethnicity, serum calcium and phosphate concentrations and types of phosphate binders (calcium- or non-calcium-based). In addition, we presented the Pearson partial correlation coefficient between serum FGF23 and each of serum calcium (adjusted for sex and phosphate based on the results of the ANCOVA) and serum phosphate (adjusted for sex and calcium based on the results of the ANCOVA) concentrations at screening.

To analyze the effect of tenapanor on serum FGF23 concentrations from post-phosphate-binder washout to the end of treatment, we performed an ANCOVA on FGF23 change at the end of treatment, with treatment as a fixed factor and post-washout serum FGF23 concentration as a covariate. Within the framework of the ANCOVA model, we performed a pairwise comparison between each tenapanor dose and placebo using a *t-*test with a significance level of 0.05, as described previously, unless otherwise specified \[[@gfy061-B27]\].

To investigate the correlation between changes in serum FGF23 and serum phosphate concentrations from post-washout to the end of treatment, we plotted changes in natural log-transformed serum FGF23 against changes in serum phosphate and calculated the Pearson correlation coefficient (*ρ*).

RESULTS
=======

Patient disposition and serum phosphate
---------------------------------------

Following a 1- to 3-week washout of phosphate binders, 162 patients who met the criteria to continue the study (serum phosphate 6.0 to  \<10 mg/dL) were randomly assigned to receive 4 weeks of treatment with either placebo or tenapanor at doses of 3 or 30 mg once daily, or 1, 3, 10 or 30 mg twice daily (seven groups in total). The mean (standard deviation) age of participants in the study population was 59.1 (13.7) years and 64% were men. A total of 115 patients (71%) completed the study. Clinical characteristics of the randomized groups have been reported previously; they were well-balanced across all demographic and clinical characteristics \[[@gfy061-B27]\]. During the treatment period, gastrointestinal disorders were the most common adverse event type (by system organ class) in the tenapanor groups (tenapanor-treated groups, 23--76%; placebo group, 19%), with diarrhea the most frequent adverse event (tenapanor-treated groups, 18--68%; placebo group, 12%), particularly at the highest doses of tenapanor (10 mg twice daily, 48%; 30 mg once daily, 52%; 30 mg twice daily, 68%) \[[@gfy061-B27]\]. A total of 19 patients (12%) discontinued treatment owing to diarrhea, with the highest rates of discontinuation in the two highest-dose tenapanor groups (30 mg once daily, 29%; 30 mg twice daily, 32%). Other types of adverse events were uncommon, with the adverse event profile of tenapanor otherwise similar to that of placebo \[[@gfy061-B27]\].

At the end of the washout period, mean serum phosphate concentrations were 7.32--7.92 mg/dL in the tenapanor-treated groups and 7.87 mg/dL in the placebo-treated group. Tenapanor treatment decreased serum phosphate concentrations from the post-washout level in a dose-dependent manner (least-squares mean changes: tenapanor-treated groups, −0.47 to −1.98 mg/dL; placebo group, −0.54 mg/dL; P = 0.01, ANCOVA; F*-*test). The most pronounced reductions in serum phosphate from the post-washout level were observed in the tenapanor 10 and 30 mg twice daily dosing groups (each P \< 0.05 versus placebo, ANCOVA; *t-*test) \[[@gfy061-B27]\].

Serum FGF23 at screening and following phosphate-binder washout
---------------------------------------------------------------

Serum-intact FGF23 concentrations throughout the study are presented in [Figure 1](#gfy061-F1){ref-type="fig"}. At screening, the geometric mean serum intact FGF23 (CV, percentage) was 1996 pg/mL (274%) for all patients analyzed as a single group \[*n* = 147 (screening samples with complete FGF23 measurements)\], and the range of geometric means for all groups was 1430--2605 pg/mL. Men had significantly higher serum FGF23 concentrations at screening than women \[geometric means (CV, percentage): men, 2432 pg/mL (222%); women, 1407 pg/mL (360%); P= 0.005\]. Screening FGF23 concentrations correlated directly with serum concentrations of calcium and phosphate (Pearson partial correlation coefficients: calcium, 0.35; phosphate, 0.69; both P \< 0.001). No significant differences were observed in serum FGF23 at screening by race, age or use of calcium-based versus non-calcium-based phosphate binders (P values all \>0.05).

![Serum FGF23 concentrations at screening, post-phosphate-binder washout and at the end of study treatment with tenapanor or placebo. Geometric means (CV, percentage) at post-washout reported previously \[[@gfy061-B27]\]. b.i.d., twice daily; EOT/ET, end of treatment/early termination; q.d., once daily.](gfy061f1){#gfy061-F1}

Serum FGF23 concentrations increased for all groups from screening to post-phosphate-binder washout ([Figure 1](#gfy061-F1){ref-type="fig"}), with geometric means of FGF23 approximately doubling by the end of the washout period. For all patients analyzed as a single group \[*n *=146 (post-washout samples with complete FGF23 measurements)\], geometric mean serum FGF23 (CV, percentage) was 4201 pg/mL (245%) after phosphate-binder washout compared with 1996 pg/mL (274%) at screening (P* *\< 0.001); the range of post-washout geometric means for all groups was 2601--6294 pg/mL \[[@gfy061-B27]\].

Effect of tenapanor or placebo on serum FGF23
---------------------------------------------

Up to 4 weeks of tenapanor treatment decreased serum FGF23 concentrations from post-phosphate-binder washout (range of geometric means for all tenapanor groups after tenapanor treatment: 2030--3563 pg/mL), whereas FGF23 continued to increase in patients receiving placebo (geometric mean: after placebo treatment, 6930 pg/mL; after phosphate-binder washout, 4937 pg/mL; [Figure 1](#gfy061-F1){ref-type="fig"}). Similar results were observed when an ANCOVA was performed on the change in FGF23 from post-washout to the end of treatment ([Figure 2](#gfy061-F2){ref-type="fig"}). There was a 21.9% increase in geometric mean FGF23 for the placebo group and a 9.1--27.9% decrease in geometric mean FGF23 for the tenapanor-treated groups. Tenapanor doses of at least 3 mg twice daily were required to decrease FGF23 concentrations substantially compared with post-washout levels ([Figure 2](#gfy061-F2){ref-type="fig"}), whereas all tenapanor doses significantly decreased FGF23 compared with placebo (P ≤ 0.001--0.04; [Figure 2](#gfy061-F2){ref-type="fig"}). At the end of the study, serum FGF23 concentrations had not completely returned to screening levels in the groups treated with tenapanor ([Figure 1](#gfy061-F1){ref-type="fig"}). When all tenapanor- and placebo-treated patients were considered, the change in serum FGF23 concentrations from post-phosphate-binder washout to the end of treatment correlated with concomitant changes in serum phosphate (*ρ* = 0.48, P \< 0.001; [Figure 3](#gfy061-F3){ref-type="fig"}).

![Forest plots of ratios of geometric mean of serum FGF23 concentration following treatment with tenapanor or placebo. Data are presented as ratios (with 95% confidence intervals), which can be converted to percentage changes from post-washout or placebo treatment. ANCOVA was performed on data for the change from post-washout in natural log-transformed FGF23 concentration at the end of treatment/early termination, with treatment as a fixed factor and post-washout FGF23 (natural log-transformed) as a covariate. Ratios for change from post-washout reported previously \[[@gfy061-B27]\]. b.i.d., twice daily; CI, confidence interval; EOT/ET, end of treatment/early termination; q.d., once daily.](gfy061f2){#gfy061-F2}

![Scatter plot of changes in serum FGF23 (natural log transformed) and phosphate concentrations from post-phosphate-binder washout to the end of treatment/early termination for all study participants. The change in serum FGF23 concentrations from post-phosphate-binder washout to the end of treatment correlated with concomitant changes in serum phosphate (Pearson correlation coefficient, *ρ*  =  0.48; P  \< 0.001). b.i.d., twice daily; q.d., once daily.](gfy061f3){#gfy061-F3}

DISCUSSION
==========

This secondary analysis of a Phase 2 placebo-controlled randomized clinical trial of tenapanor in patients receiving hemodialysis with hyperphosphatemia provides important new findings relating to the management of disordered phosphate homeostasis in patients receiving hemodialysis. The ability of non-calcium-based phosphate binders to lower elevated FGF23 concentrations in patients with CKD has been inconsistent, and calcium-based phosphate binders may actually increase FGF23 \[[@gfy061-B22]\]. Here, we provide, to our knowledge, the first data showing that FGF23 markedly and rapidly increases following 1--3 weeks of withdrawal from maintenance phosphate-binder therapy, which provides indirect clinical evidence of a beneficial effect of phosphate binders on FGF23 control. We also report that in this study tenapanor significantly lowered FGF23 versus placebo following just 4 weeks of treatment. In aggregate, these data provide strong support for the overarching approach of targeting reduction of dietary phosphate absorption as a strategy to lower serum FGF23 concentrations in parallel with serum phosphate in patients with CKD.

Consistent with our hypothesis, the magnitude of FGF23 reduction correlated with the magnitude of change in serum phosphate. The degree of FGF23 reduction in this study compared favorably to that in other studies with similarly brief durations of treatment \[[@gfy061-B22], [@gfy061-B29], [@gfy061-B30]\]. In a study of patients undergoing hemodialysis with iron deficiency \[[@gfy061-B31]\], median intact FGF23 concentration decreased from 2000 pg/mL at baseline to 1771 pg/mL (P = 0.01) 12 weeks after the phosphate binder they were taking was changed from sevelamer hydrochloride to ferric citrate hydrate, consistent with a reduction in median intact FGF23 of ∼11% \[[@gfy061-B31]\]. In other studies in normophosphatemic patients with CKD Stage 3 or 4, reductions in median intact FGF23 of ∼40% were achieved after 6 weeks of treatment with sevelamer hydrochloride \[[@gfy061-B30]\], while 4 weeks of treatment with lanthanum carbonate resulted in reductions in median C-terminal FGF23 levels of 22% relative to baseline \[[@gfy061-B32]\]. In contrast, following 1 year of randomized treatment with either calcium acetate or sevelamer hydrochloride, patients receiving hemodialysis experienced a significant reduction in median intact FGF23 from 16 478 pg/mL at baseline to 5378 pg/mL (P\< 0.0001), consistent with a reduction of ∼67% \[[@gfy061-B33]\]. However, because many patients in that study changed their dialysate calcium concentration from 3.5 to 2.5 mEq/L, and many withdrew calcitriol treatment for the entire year of investigation, it is difficult to ascertain the magnitude of FGF23 reduction that can be attributed to each of the simultaneous interventions. It is also unknown how much of the FGF23 reduction occurred within the first 4 weeks of phosphate-binder treatment. In a separate study in patients with Stage 3 nondiabetic CKD treated with sevelamer carbonate or placebo for 40 weeks, the modest yet significant reduction in FGF23 concentration in patients receiving sevelamer relative to placebo was not accompanied by a significant effect on left ventricular mass \[[@gfy061-B34]\]. Further studies are thus needed to evaluate whether tenapanor-induced reductions in FGF23 are associated with improvements in cardiovascular parameters, such as left ventricular mass.

Although tenapanor did not decrease serum FGF23 to pre-phosphate-binder washout concentrations, it is important to acknowledge that we investigated only a 4-week course of treatment after abruptly stopping phosphate binders that patients may have been taking for years, and that FGF23 continued to increase in patients receiving placebo. These findings suggest that pharmacological lowering of elevated FGF23 in patients with CKD may require more time than that required for FGF23 to rise in the absence of treatment. It is also currently unclear how to optimally and consistently reduce FGF23, with the most effective therapies described so far being calcimimetics, which can provide sustained reductions in serum calcium and serum phosphate and subsequently FGF23. The calcimimetic cinacalcet reduced median intact FGF23 concentration from 5555 pg/mL at baseline to 2255 pg/mL after 20 weeks of treatment (P \< 0.001 versus placebo) in patients receiving hemodialysis with secondary hyperparathyroidism. The magnitude of the FGF23 reduction induced by cinacalcet was associated with a reduced risk of cardiovascular events, supporting a therapeutic benefit of reducing serum FGF23 concentrations in patients receiving hemodialysis \[[@gfy061-B35]\]. Similarly, a second-generation intravenous calcimimetic, etelcalcetide, lowered median intact FGF23 concentrations from 4032 pg/mL at baseline to 938 pg/mL after 12 weeks of treatment of patients receiving hemodialysis with secondary hyperparathyroidism \[[@gfy061-B36]\]. Longer-term studies of tenapanor are, therefore, needed to elucidate whether progressive and lasting reductions in serum FGF23 concentrations are achievable and are associated with improved clinical outcomes.

Phosphate lowering is only one component of an effective long-term treatment strategy to reduce FGF23. A number of other factors are known to stimulate FGF23 in patients receiving dialysis including serum calcium concentration, calcium load, vitamin D, iron status and inflammation (see reviews by Wolf \[[@gfy061-B2]\] and Francis and David \[[@gfy061-B37]\]). Other non-pharmacological interventions may also affect FGF23 concentrations. For example, a study by the Frequent Hemodialysis Network Trial Group showed that patients who had hemodialysis six times per week had improved control of hypertension and hyperphosphatemia and a lower risk of death or increased left ventricular mass relative to patients who had dialysis three times per week \[[@gfy061-B38]\]. Furthermore, diet was shown to influence FGF23 concentrations in a two-way crossover study of patients with advanced CKD in which patients received a 1-week meat-based diet and a 1-week vegetarian-based diet with equivalent nutritional content; serum phosphate and FGF23 concentrations were significantly higher after the meat-based period than after the vegetable-based diet period \[[@gfy061-B39]\].

As described in the primary article \[[@gfy061-B27]\], gastrointestinal disorders, particularly diarrhea, were the most common adverse events recorded during the treatment period of our study. The frequent occurrence of looser and less formed stools is consistent with the mechanism of action of tenapanor, which increases stool sodium and water content \[[@gfy061-B24], [@gfy061-B25]\]. These pharmacological effects of tenapanor were also confirmed in a study in patients receiving hemodialysis; however, the same study also showed these effects were not accompanied by detectable differences in interdialytic weight gain between patients receiving tenapanor and those receiving placebo \[[@gfy061-B23]\]. In a recent study in patients receiving hemodialysis, the effect of tenapanor on the changes in stool form and frequency were characterized utilizing an electronic telephone diary \[[@gfy061-B40]\]. Results from this study indicate that, although in the clinical trial setting the term diarrhea is used to characterize these stool changes, tenapanor causes softer, more frequent bowel movements that, on average, remained within the normal range with regard to both frequency and form \[[@gfy061-B40]\]. Notwithstanding these considerations, the high rates of diarrhea observed in our study in patients receiving high doses of tenapanor represent a potential therapy limiting factor. It will be important for future studies to monitor whether stool form and frequency changes will limit the ability of tenapanor to reduce FGF23 concentrations.

In our study, we performed the key statistical analyses of FGF23 using geometric means. The geometric mean was used because FGF23 data are typically highly skewed and the natural log-transformed FGF23 data are approximately normally distributed. The central tendency of data with a log--normal distribution is best represented by the geometric mean. On the other hand, the median---included in our article as a secondary statistic---is often presented as the primary statistic when a distribution-free (non-parametric) analysis is performed, but such an analysis is in general less efficient than a parametric one if the assumed parametric distribution is true. Beyond the strengths of this randomized study, we also acknowledge certain limitations. Although collection of serum samples for analysis of biomarkers was pre-specified at the start of the study, all analyses of FGF23 data were conducted *post hoc*. We measured FGF23 using an intact assay. As reviewed by Smith \[[@gfy061-B41]\], the selection of intact versus C-terminal assays for measurement of serum FGF23 is a controversial topic and assays of intact versus C-terminal FGF23 can show poor analytical agreement. Other limitations related to this clinical trial, such as its lack of tenapanor dose titration and higher proportion of men than women in all treatment groups, have been acknowledged previously \[[@gfy061-B27]\] and are also relevant to this analysis. Additionally, the number of patients per group (∼*n* = 20) was modest; however, when analysing all tenapanor-treated patients as a single group as part of the analysis of FGF23 from screening to end of phosphate-binder washout, the sample size was relatively large (*n* = 147).

In summary, we demonstrate that serum FGF23 concentrations increase markedly and rapidly following withdrawal of maintenance phosphate-binder therapy in patients receiving hemodialysis with hyperphosphatemia. Subsequent tenapanor treatment significantly decreased serum FGF23 concentrations. Together, these data help to illustrate the importance of dietary phosphate intake and serum phosphate as important regulators of serum FGF23, and suggest that reductions in dietary phosphate absorption with tenapanor, through a mechanism distinct from direct gastrointestinal phosphate binding, may aid in the control of FGF23 in patients receiving dialysis. In future studies, we will test the hypothesis that longer-term treatment with tenapanor achieves progressive and lasting reductions in serum FGF23 concentrations \[[@gfy061-B42]\].
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